Shares in $ACW are this morning trading up over 200%

Sector Reports > Latest News > ASX > Shares in $ACW are this morning trading up over 200%

Sector Reports are pleased to announce our coverage on the below stocks.

For daily updates, news, trade ideas and complimentary research reports please insert your email in the box below and get instant access to our latest research reports, which include Cannabis, AI, Gold, Gambling and more.

Enter Your Email for Instant Access to the Best Free ASX Research on the Markets

Shares in ACW are this morning trading up over 200% from their closing price yesterday. The company released an update regarding their Xanamem product.

The key points the company focused on in the release were.


  • Statistically significant results demonstrate cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily in the XanaHES dose escalation study
  • Statistically significant reduction in serum cortisol following treatment with Xanamem 20mg daily
  • Xanamem 20mg daily continues to exhibit a good safety profile with no serious adverse events observed
  • Results significantly enhance the Xanamem dataset and help shape Actinogen’s drug development strategy for the treatment of Alzheimer’s disease and other neurological and metabolic diseases associated with cognitive impairment
  • Company to host a Conference Call on October 1st, 2019 (today) at 10:30am (AEST)


Enter Your Email for Instant Access to the Best Free ASX Research on the Markets



This website is a service of Profectus Solutions Pty. Ltd. an investor relations group and media firm. The website or article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Profectus is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Profectus Solutions or through or from the service shall create any warranty not expressly stated.

Profectus Solutions do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Profectus does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Conflict of interest

Directors, staff or third parties of Profectus may at times own shares of companies that are profiled within our network. We as part of our business model actively seek to do business with listed ASX or other companies.

We have NOT been compensated for the production of this webpage.

Leave a Reply

Your email address will not be published.